Skip to main content
Beijing SL Pharmaceutical Co., Ltd. logo

Beijing SL Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002038 ISIN · CNE000001L31 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,472 across all filing types
Latest filing 2014-04-25 Management Reports
Country CN China
Listing Shenzhen Stock Exchange 002038

About Beijing SL Pharmaceutical Co., Ltd.

https://www.slpharm.com.cn

Beijing SL Pharmaceutical Co., Ltd. specializes in the research, development, manufacturing, and commercialization of pharmaceutical products. The company focuses on several therapeutic areas, including cardiovascular and cerebrovascular diseases, oncology, and infectious diseases. Its product portfolio features a range of chemical drugs and active pharmaceutical ingredients (APIs), with key offerings such as clopidogrel bisulfate and amlodipine besylate. Operating with advanced production facilities that adhere to international Good Manufacturing Practice (GMP) standards, the company emphasizes technological innovation and quality control. The organization serves both domestic and international markets, leveraging its integrated R&D platform to develop generic medications and innovative formulations aimed at improving patient outcomes.

Recent filings

Filing Released Lang Actions
独立董事张鸣溪2013年度述职报告
Management Reports Classification · 95% confidence The document is a detailed report by an independent director of Beijing SL Pharmaceutical Co., Ltd. for the year 2013. It includes the director's attendance at meetings, independent opinions on various company matters such as profit distribution, securities investment, internal control self-evaluation, appointment of directors, audit firm appointment, related party transactions, external guarantees, entrusted loans, and protection of public investors' rights. The report references compliance with laws, regulations, and company articles, and provides a comprehensive review of the director's duties and opinions over the fiscal year 2013. The content is substantive, detailed, and covers governance and audit-related matters for the full fiscal year, consistent with a Management Report or similar detailed governance and oversight report. It is not a full Annual Report (10-K) or Audit Report (AR) but rather a Management Report by an independent director. Therefore, the best fitting category is Management Reports (MDA).
2014-04-25 Chinese
2013年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2013年度内部控制评价报告' which translates to '2013 Annual Internal Control Evaluation Report' for Beijing SL Pharmaceutical Co., Ltd. It contains detailed descriptions of the company's internal control environment, risk assessment, control activities, information and communication, and internal supervision. It also includes specific standards for identifying internal control deficiencies related to financial and non-financial reporting, and concludes with the board's evaluation that no major deficiencies exist. The document is comprehensive, contains substantive content about internal controls, and is not merely an announcement or certification. This type of report aligns with an Audit Report / Information (AR) category, as it is a standalone internal control evaluation report, not a full annual report or other filing type. Therefore, the appropriate classification is AR with high confidence. FY 2013
2014-04-25 Chinese
关于召开2013年年度股东大会的通知
AGM Information Classification · 100% confidence The document is a notice about the convening of the 2013 Annual General Meeting (AGM) of Beijing SL Pharmaceutical Co., Ltd. It includes details about the meeting date, location, agenda items to be discussed (such as the 2013 annual board report, supervisory board report, financial statements, profit distribution plan, and annual report summary), and instructions for shareholder registration and proxy voting. The document does not contain the actual annual report or financial statements but rather serves as an official announcement to shareholders about the upcoming AGM and the matters to be voted on. The document length is relatively short (3213 characters), and it is clearly a meeting notice rather than the report itself. Therefore, it fits the category of AGM Information (AGM-R).
2014-04-25 Chinese
关于全资子公司对华润普仁鸿（北京）医药有限公司委托贷款的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding a related-party entrusted loan transaction by Beijing Shuanglu Pharmaceutical Co., Ltd. It details the loan amount, terms, borrower information, risk assessment, board and independent directors' opinions, and compliance with regulatory requirements. The document is a formal disclosure of a financing transaction involving a subsidiary and a related party, including approval procedures and risk controls. It does not contain financial statements or comprehensive financial performance data, nor is it a transcript, report, or presentation. It is an update on a capital/financing activity, specifically a loan transaction. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is under 5,000 characters but contains substantive content about the financing, not just an announcement of a report publication or a certification, so it is not RPA or RNS.
2014-04-25 Chinese
关于2013年度母公司经营情况及子公司发展情况的说明
Management Reports Classification · 90% confidence The document is a company announcement from Beijing Shuanglu Pharmaceutical Co., Ltd. regarding the 2013 annual operating conditions of the parent company and the development status of its subsidiaries. It includes financial data for 2013, such as operating profit, total profit, and net profit, but these figures are noted as internally audited and not yet audited by an accounting firm. The document also discusses subsidiary losses, development progress, and forecasts for 2014 and 2015. The length is 1511 characters, which is relatively short and the content is a narrative explanation rather than a full formal annual report with comprehensive financial statements. It does not appear to be a full Annual Report (10-K) or Interim Report (IR), nor is it a simple announcement of a report publication. The document is more of a management explanation and commentary on financial results and business trends, which aligns with the Management Reports (MDA) category.
2014-03-03 Chinese
2013年度业绩快报
Earnings Release Classification · 95% confidence The document is titled '2013 年度业绩快报' which translates to '2013 Annual Performance Express Report' or 'Annual Earnings Quick Report'. It contains preliminary financial data for the full fiscal year 2013, including revenue, profit, net income, earnings per share, and asset information. The document explicitly states that the data is preliminary and audited internally but not yet audited by an external accounting firm, and it mentions that final data will be disclosed in the annual report. The length is 1605 characters, which is short and typical for an earnings release or earnings quick report rather than a full annual report. The document does not contain full financial statements or detailed analysis but provides key financial highlights and performance metrics for the year. This matches the definition of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only. It is not a full Annual Report (10-K) or Interim Report (IR) because it lacks comprehensive financial statements and detailed analysis. It is not a Report Publication Announcement (RPA) because it contains actual financial data, not just a notice of report availability. Therefore, the correct classification is Earnings Release (ER). FY 2013
2014-02-27 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.